23andMe Adds BRCA Breast/Ovarian Cancer Testing to Service | GenomeWeb

Consumer genomics firm 23andMe has begun offering BRCA1 and BRCA2 testing to help customers ascertain their risk of developing breast or ovarian cancer.

On its website, the company said its service tests for the i4000377, i4000378, and i4000379 SNPs in those genes, either one of which may "influence your carrier status for breast/ovarian cancer."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.